URO TODAY: An experiment that combines a standard advanced prostate cancer drug treatment with a vaccine to assist the immune system has just begun in the US. READ MORE> Looking to harness the body’s own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators [...]
Archive for the ‘Prostate drugs’ Category
Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer
Posted in Chemotherapy, Hormone therapy, Hormone-refactory, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration, castration-resistant disease, catheter, Chemotherapy, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, URO TODAY on May 29, 2010 | Leave a Comment »
URO TODAY: Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have not had chemotherapy. A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>
European drug cos will develop and sell new prostate cancer growth inhibitor
Posted in PROSTATE CANCER, Prostate drugs, Treatment news, tagged Debio 0931, Debiopharm Group, Ipsen (Euronext:IPN), prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate drug, prostate treatment, tumour inhibitor on September 8, 2009 | Leave a Comment »
REUTERS: Two big European drug companies have concluded a deal to develop and sell Debio 0931, which inhibits the growth of tumours in cancers like prostate cancer.
Second trial announced for promising hormone drug to treat advanced prostate cancer
Posted in Hormone therapy, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, Bone loss, cancer research, GTx-758, hot flashes, New Prostate Cancer Info-link, oral luteinizing hormone inhibitor, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, second Phase I clinical trial on July 8, 2009 | Leave a Comment »
JULY 8: NEW PROSTATE CANCER INFOLINK: A second Phase I clinical trial has been announced for GTx-758 – an oral luteinizing hormone inhibitor – which is designed for first-line treatment of advanced prostate cancer.
New research seems to clear drug of causing more aggressive prostate cancer
Posted in PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Treatment debate, tagged cancer research, finasteride, HULIQ NEWS:, more aggressive cancer, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer drug, prostate cancer treatments, prostate treatment, prostate treatment debate on July 8, 2009 | Leave a Comment »
JULY 8: HULIQ NEWS: New research into prostate cancer drug finasteride – earlier thought to cause aggressive cancer in some patients – suggests doctors can be less cautious about using it.
PROSTATE FUTURE: New drug will be ready for baby boomers
Posted in Immunotherapy, New prostate drugs, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, Baby Boomers, cancer research, Dendreon, immunotherapy vaccines, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge treatment, U.S. Food and Drug Administration on June 11, 2009 | Leave a Comment »
JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likely receive US Food and Drug Administration approval and become widely available just as the first Baby Boomers reach 65 in 2010.









